For the third consecutive year, the World Bladder Cancer Patient Coalition is thrilled to offer the Bladder Cancer Awareness Month Grants (BCAM Grant) for 2024. The BCAM Grant aims to enable patient organisations, support, or advocacy groups in low and middle-income countries to bring awareness to bladder cancer in their communities.
Every year, more than 614,000 people receive bladder cancer diagnosis around the world. For many patients, their diagnosis will be the very first time they hear about bladder cancer.
This International Women’s Day, we are proud to share a meaningful initiative illuminating the experiences of women affected by bladder cancer. Our new campaign follows five women in five different corners of the world who share their very personal experiences with bladder cancer.
One in four bladder cancer patients are women, yet their stories often go unheard. Women face numerous challenges throughout their entire care journey. Alarmingly, their symptoms are frequently attributed to other causes,
Since 2008, Rare Disease Day, which takes place on the last day of February, has brought together patients, caregivers, family members, friends, and advocates worldwide. This leap year it is truly rare disease – February 29. The World Bladder Cancer Patient Coalition supports the Rare Disease Day international campaign that aims at increasing awareness among the general public and decision-makers about rare diseases and their influence on the lives of families living with these conditions.
Bladder Cancer is the 9th most commonly diagnosed cancer in the world with 614,000 people diagnosed each year. Around the world, the 1.9 million people living with the condition have their own journeys and personal bladder cancer stories to share.
Below we are honoured to share the bladder cancer journey of Amit. Bladder cancer stories are a powerful reminder of the impact of bladder cancer and also help raise awareness of bladder cancer and highlight the urgent need for new treatments and research,
The International Agency for Research on Cancer (IARC) has recently published the updated GLOBOCAN 2022 with new estimates on the global cancer burden, indicating that it has risen to 19.9 million cases and 9.7 million cancer deaths in 2022.
The International Agency for Research on Cancer estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 9 men and 1 in 12 women die from the disease.
World Cancer Day is an opportunity to bring attention to bladder cancer and experiences of the people affected by it with a call to close the care gap. Over 500,000 people are diagnosed with bladder cancer around the world annually. This World Cancer Day, the World Bladder Cancer Patient Coalition is proud to join the international cancer community efforts. Jointly, we advocate for greater access to care for marginalised populations and closing the gap in cancer care worldwide.
The World Bladder Cancer Patient Coalition (WBCPC) together with our member organisation, Norwegian Bladder Cancer Society, joined the Community Advisory Board (CAB) meeting of the EU-funded project PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials) that took place in Oslo, Norway on January 24-26, 2024. Jointly, both organisations shared unique experiences and needs of patients with advanced bladder cancer. The PRIME-ROSE project aims to help advanced cancer patients who have tried all standard treatments and could benefit from precision cancer medicine (PCM).
On the occasion of World Cancer Day on February 4, 2024, the World Bladder Cancer Patient Coalition (WBCPC) is proud to join forces with the international cancer community to raise awareness. Join us in raising bladder cancer awareness and the campaign to close the equity gaps that exist in cancer care around the world.
World Cancer Day 2024 organised by the Union for International Cancer Control (UICC) marks the third and last year of the ‘Close the care gap’ campaign centered on the issue of equity.
The World Bladder Cancer Patient Coalition (WBCPC) actively participated in the WECAN Evidence-Based Advocacy Training Workshop in Munich, Germany, on January 18-19, 2024. This event is part of the WECAN training programme to enhance the knowledge and capacity of patient advocates to conduct patient-led research.
WECAN – Working Group of European Cancer Advocacy Network’s objective is to develop a strong community of well-trained patient advocates. Alex Filicevas, Executive Director of WBCPC,
